Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...

Avalyn Pharma is led by CEO Lyn Baranowski, who previously worked at Pearl Therapeutics, where she helped develop treatments ...

Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited ...

BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.

Baseimmune, a biotechnology company leveraging computational protein design to create next-generation immunotherapies, today unveiled its new fibrosis-focused pipeline, beginning with IPF. IPF is a ...

Avalyn Pharma is eyeing an IPO as the biotech seeks more funds to take its inhaled versions of approved drugs for lung ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

Figure 3. Conceptual framework for aging alignment in disease models and therapeutic development. This schematic illustrates the spectrum of aging-related diseases (ARDs) based on their mechanistic ...

IPF is a chronic, progressive lung disease marked by lung tissue thickening and scarring, leading to reduced lung function. It is a specific type of interstitial lung disease, which includes various ...